Diabetic Foot Ulcer (DFU)NCT07046403
Multicentric RCT Comparing High Purity Type I Collagen-Skin Substitute vs dHACM in Treatment of Diabetic Foot Ulcers
A study testing High Purity Type-I Collagen-based Skin Substitute and SOC and Dehydrated Human Amnion / Chorion Membrane and SOC in people with Diabetic Foot Ulcer (DFU), run by Adichunchanagiri Institute of Medical Sciences, B G Nagara at 4 sites in India.
Trial summary
This is a randomized controlled clinical investigation in patients suffering from diabetic foot ulcers at multiple centers. The study intends to compare patient outcome data using Standard of Care with Type-I Collagen-based Skin Substitute and Standard of Care with Dehydrated Human Amnion/Chorion Membrane. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Diabetic Foot Ulcer (DFU)
- What is being tested?
- High Purity Type-I Collagen-based Skin Substitute and SOC and Dehydrated Human Amnion / Chorion Membrane and SOC
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 4 sitesIndia
- Study dates
- 5 Jul 2025to 3 Oct 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must be at least 18 years of age or older.
- Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
- At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 10.0 cm2 measured post debridement using a ruler to measure wound area.
- The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
- The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
- The target ulcer must be full thickness on the foot or ankle that does not probe to bone.
Show all 13Show fewer
- Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:
- Transcutaneous Oxygen Measurement (TCOM) ≥30 mmHg Ankle-Brachial Index (ABI) between 0.7 and 1.3 Peripheral Vascular Resistance (PVR): Biphasic Toe-Brachial Index (TBI) ˃0.6 As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle of the target extremity.
- If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
- The subject must consent to using the prescribed off-loading method for the duration of the study.
- The subject must agree to attend the twice-weekly/weekly study visits required by the protocol.
- The subject must be willing and able to participate in the informed consent process.
- Patients must have read and signed the IRB approved ICF before screening procedures are undertaken.
Who cannot join
- A subject known to have a life expectancy of <6 months.
- If the target ulcer is infected or if there is cellulitis in the surrounding skin.
- Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
- A subject that has an infection in the target ulcer that requires systemic antibiotic therapy.
- A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy.
- Topical application of steroids to the ulcer surface within one month of initial screening.
Show all 15Show fewer
- A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
- A subject with a glycated hemoglobin (HbA1c) greater than or equal to 13% taken at or within 3 months of the initial screening visit.
- A subject with a serum creatinine ≥ 3.0mg/dL within 6 months of the initial screening visit.
- A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer.
- Women who are pregnant or considering becoming pregnant within the next 6 months.
- A subject with end stage renal disease requiring dialysis.
- A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
- A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.
- A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit.
Trial locations and contacts
4 sites in 1 country.
India4 sites
RajaRajeswari Medical College and Hospital
Bangalore, Karnataka, 560074
Adichunchanagiri Institute of Medical Sciences
Mandya, Karnataka, 571448
Mysore Medical College and Research Institute
Mysore, Karnataka, 570001
JSS Medical College Hospital
Mysore, Karnataka, 570004
About this study
Official title: A Multicentric Randomized Controlled Clinical Trial Comparing the Use of High Purity Type-I Collagen-Based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers
This is a randomized controlled clinical investigation in patients suffering from diabetic foot ulcers at multiple centers. The study intends to compare patient outcome data using Standard of Care with Type-I Collagen-based Skin Substitute and Standard of Care with Dehydrated Human Amnion/Chorion Membrane.
Read the detailed description
The purpose of the present study is to compare the safety and efficacy of high-purity type-I collagen-based skin substitutes (HPTC), which are free from contaminants such as lipids, elastin, and other immunogenic particles, versus dehydrated human amnion/chorion membrane (dHACM) in the treatment of DFUs. This multicentric randomized, controlled clinical trial seeks to provide valuable insights into the best treatment strategy for enhancing healing outcomes and reducing the challenges posed by chronic DFUs.
Study will be carried out as a multicentric randomized, controlled open-label study to evaluate the safety and effectiveness of High Purity Type-I Collagen-based Skin Substitute (HPTC) compared to Dehydrated Human Amnion/Chorion Membrane (dHACM) for treating diabetic foot ulcers (DFUs). The trial will include patients with DFUs treated by wound care specialists at Adichunchanagiri Institute of Medical Sciences (AIMS), B. G. Nagara, Rajarajeswari Medical College and Hospital (RRMCH), Bangalore, JSS Medical College and Hospital (JSS), Mysore and Mysore Medical College and Research Institute (MMC\&RI), Mysore, under the supervision of primary investigator Dr Naveen N. the other principal investigators include Dr Kamal Kumar M, Dr Ravi Shivaiah and Dr Vijay Kumar, respectively. Informed consent will be obtained from all participants prior to any study-related procedures at each of the 3 centres. Each patient will sign an Institutional Ethics Committee / Investigational Review Board (IEC/IRB)-approved consent form, at respective participating centres. IEC/IRB of Adichunchanagiri Institute of Medical Sciences, B. G. Nagara, will be the Designated Ethics Committee (DEC).
The study population will consist of patients seeking treatment for DFUs. Eligible patients will be those willing to participate and comply with scheduled visits on days 7, 10, 14, 17, 21, and 28. The study will include two phases: screening and treatment.
The screening phase aimed to determine patient eligibility for the treatment phase.
Centralized computer-generated block randomization, stratified by centre in a 1:1 ratio will be done. Due to the nature of the interventions, blinding of participants and clinicians is not feasible. However, outcome assessors and data analysts will be blinded to treatment allocation to minimize bias.
The treatment phase of the study will commence with a series of evaluations to ensure patients remained eligible. Participants who will continue to meet the inclusion criteria after the screening phase will be randomly assigned to one of two groups:
- Standard of Care (SOC) with High Purity Type-I Collagen-based Skin Substitute (HPTC).
- Standard of Care (SOC) with Dehydrated Human Amnion/Chorion Membrane (dHACM). Neither the patients nor the clinicians will be blinded to group assignments. The randomization will follow a balanced schedule, using permuted blocks of 12. When a patient will be ready for randomization, the study site will contact a representative from the sponsor, who will open a sequentially numbered opaque envelope to disclose the group assignment, maintaining allocation concealment.
Throughout the 4-week treatment phase, patients will be reassessed on days 7, 10, 14, 17, 21, and 28. The SOC dressing applied in both groups consisted of a three-layer system:
- First layer: Non-adherent, porous paraffin gauze.
- Second layer: Absorbent gauze pads.
- Third layer: Soft roll and Crepe bandage. If the study ulcer was found to be 100% re-epithelialized during the visit, no further study procedures will be conducted at that time. The patient will then be scheduled for a follow-up visit after one week to confirm the healing.
If full healing was not achieved, an evaluation will be carried out to check for any signs of clinical infection. If an infection is confirmed, treatment with topical antimicrobials or oral antibiotics will be permitted, though the use of topical antibiotics will be prohibited.
After this infection assessment, the ulcer would be cleaned, photographed, and debrided at the investigator's discretion to ensure a clean and granulating wound base with minimal adherent slough. The Standard of Care (SOC) will be then re-applied, and patients will be instructed to keep the bandage dry. Additionally, they will be advised to contact or return to the study site if the bandage became soiled or removed.
Study Completion Patients will complete the study 4 weeks after their initial treatment visit. However, if a patient's study ulcer healed before the 4-week period, they will be considered to have completed the study at the time of full healing.
Complete healing will be defined as 100% re-epithelialization of the ulcer with no drainage. Throughout the study, patients will retain the right to decline participation or withdraw at any time without prejudice.
In the event of a patient's withdrawal, their last recorded wound measurement will be carried forward to determine the change in wound size and calculate their final outcome.
Study Outcomes
Primary Endpoint:
- The primary outcome of the study will be the proportion of subjects who achieved improvement in wound healing, as observed on days 7, 10, 14, 17, 21, and 28. The wound closure of the target ulcer will be continuously monitored until the end of the 4-week period.
Secondary Endpoints:
- Vascular Incursion: To assess the infiltration of vascularity in the ulcer bed on day 5 post-treatment initiation (using HPE analysis by taking 2 mm diameter punch biopsy samples).
- Time to Achieve Complete Wound Closure: Time taken for the target ulcer to achieve complete wound closure will be assessed on days 7, 10, 14, 17, 21, and 28.
- Percentage Wound Area Reduction: This will be measured weekly on days 7, 10, 14, 17, 21, and 28 using digital photography.
- Mean Number of Repeated Applications of HPTC: The average number of times the reapplication of High Purity Type-I Collagen-based Skin Substitute (HPTC) to achieve wound closure will be documented as part of the study process.
- To monitor incidence of infection or complications
- To assess patient-reported quality of life
- To evaluate scar quality using validated scales (e.g., Vancouver Scar Scale)
Exploratory Endpoint:
- The appearance, structural stability, and fragility of the newly formed skin will be documented at each visit. Any recurrence of the wound will also be monitored.
Statistical Analysis
Data will be analysed on an intention-to-treat basis. Continuous variables will be summarized using means and standard deviations or medians and interquartile ranges, as appropriate. Categorical variables will be presented as frequencies and percentages. Comparative analyses will include:
- Descriptive statistics for baseline characteristics
- Chi-square tests for categorical outcomes.
- Independent t-tests or Mann-Whitney U tests for continuous outcomes.
- Kaplan-Meier survival analysis for time-to-event data, with log-rank tests to compare groups.
Multivariable regression models will adjust for potential confounders, such as baseline wound size and patient comorbidities.
Sample Size Calculation Based on previous studies, assuming a 20% difference in the primary outcome between groups, with 60% healing in the dHACM group and 80% in the HPTC group, a sample size of 60 participants per group (total N=60) combined from the 4 centres will provide 80% power to detect this difference at a 5% significance level, accounting for a 10% dropout rate.
Ethical Considerations The study will adhere to the Declaration of Helsinki principles and Good Clinical Practice guidelines. Ethical approval will be obtained from Institutional Ethics Committee of all participating centres. Informed consent will be obtained from all participants before enrolment. Adverse events will be monitored and reported. Participant confidentiality will be maintained, and data will be anonymized. Findings will be submitted to peer-reviewed journals and presented at relevant conferences.
Timeline Recruitment: 1 month Intervention \& follow-up assessment: 3 months Data analysis and reporting: 1 month
Potential Implications This study aims to provide robust evidence on the comparative efficacy of HPTC and dHACM in managing DFUs. If HPTC proves superior to dHACM alone, it could establish a standard in treating DFUs, reducing healing time. Positive findings could influence clinical practice guidelines, offering alternative treatment options that may enhance patient outcomes and reduce healthcare costs.
- Conditions
- Diabetic Foot Ulcer (DFU)
- Being tested
- High Purity Type-I Collagen-based Skin Substitute and SOC, Dehydrated Human Amnion / Chorion Membrane and SOC
- Keywords
- Diabetic Foot Ulcer, High Purity Type-I Collagen-Based Skin Substitute, Dehydrated Human Amnion/Chorion Membrane, Randomized Controlled Clinical Trial, Multicentric Study
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Purity Type-I Collagen-based Skin Substitute and SOCDevice
The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
Dehydrated Human Amnion / Chorion Membrane and SOCDevice
The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
| Study group | Role | What they receive |
|---|---|---|
| High Purity Type-I Collagen-based Skin Substitute and SOC | Active comparator | The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) Receives: Device: High Purity Type-I Collagen-based Skin Substitute and SOC |
| Human Amnion/Chorion Membrane and SOC | Active comparator | The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) Receives: Device: Dehydrated Human Amnion / Chorion Membrane and SOC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage Change in Wound Area
The primary outcome of the study will be the percentage change in wound area, assessed at 1, 2,3, and 4 weeks, and week 5 reported measured manually with digital photography.
Measured: 5 weeks
Secondary outcomes (9)
Histopathological Analysis
Histopathological assessment will be done using biopsy on Day 0 of application to be compared with Day 5 after application of Type-I Collagen-based Skin Substitute or Human Amnion/Chorion Membrane. Histopathology assessed at day 0 and day 5, day 5 reported. Subsequently histopathology of biopsy will be done to look for:
vascular infiltration (0-3 scale) - higher score means better, neo-epithelialization (0-3 scale) - higher score means better, fibroblast activity (0-3 scale) - higher score means better, inflammatory response (0-3 scale) - lower score means better and collagen deposition (0-3 scale) - higher score means better
Measured: 5 days
Histopathological Analysis - Capillary Density (Vessels Per mm²)
Histopathological assessment will be done using biopsy on Day 0 of application to be compared with Day 5 after application of Type-I Collagen-based Skin Substitute or Human Amnion/Chorion Membrane. Histopathology assessed at day 0 and day 5, day 5 reported. Subsequently histopathology of biopsy will be done to look for capillary density (vessels per mm²) - higher count means better
Measured: 5 days
Percentage of Participants to Obtain Complete Wound Closure
The percentage of participants that obtain complete wound closure over the 5 weeks (4 weeks treatment period plus 1 week follow up)
Measured: 5 weeks
Time to Achieve Complete Wound Closure
Complete wound closure is defined as full epithelialization of the wound with no need for dressings, and sustained closure without signs of infection or breakdown.Time taken for the target ulcer to achieve this will be assessed on days 7, 14, 21, 28 and 35.
Measured: 5 weeks
Percentage of Participants Achieving ≥50% Wound Healing
Measurement of percentage of participants achieving ≥50% wound healing (epithelialization) assessed at follow up
Measured: 5 weeks
Mean Number of Applications of HPTC / dHACM
The average number of applications of High Purity Type-I Collagen-based Skin Substitute (HPTC) or dehydrated human amniotic/chorionic membrane (dHACM) to achieve wound closure will be documented as part of the study process.
Measured: 4 weeks
Number of Participants With Adverse Events
To monitor number of participants with adverse events related to the intervention (e.g., infection, allergic reactions)
Measured: 4 weeks
Patient-Reported Quality of Life Assessed Using Diabetic Foot Ulcer Scale - Short Form (DFS-SF)
The Diabetic Foot Ulcer Scale - Short Form (DFS-SF) is a validated, disease-specific health-related quality of life (HRQoL) questionnaire designed to assess the impact of diabetic foot ulcers on patients' wellbeing evaluating four validated sub-scales:
Physical Functioning Daily Activities Emotions Social Functioning
Subscale Scoring: Scores range from 0-100 for each sub-scale, with higher scores indicating better quality of life. Data were collected at baseline and at Weeks 2, 4, and 5, and week 5 results reported
Measured: 5 weeks
Healed Wound Appearance Assessment Using Vancouver Scar Scale
The resultant new skin is assessed and documented at each visit up to 5 weeks and week 5 visit reported using the Vancouver Scar Scale assessing vascularity, pigmentation, pliability and height/thickness with total score ranging from 0 to 13 (lesser the score better the scar)
Measured: 5 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study start5 Jul 2025
- Primary completion9 Sep 2025
- Study completion3 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Diabetic Foot Ulcer (DFU)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
- Sponsor type
- University, hospital or other
- Collaborators
- Mysore Medical College and Research Institute, Rajarajeswari Dental College & Hospital, JSS Medical College Hospital
- Responsible party
- Principal investigator, Dr Naveen Narayan MS, MCh (Plastic Surgery), Adichunchanagiri Institute of Medical Sciences, B G Nagara
- Investigators
- Prema Dhanraj, MS, MCh, Study chair, Rajarajeshwari Medical College and Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07046403
- Sponsor's protocol ID
- AIMS/IEC/206/2025
- Status last verified
- Nov 2025
- First submitted
- 21 Jun 2025
- Last updated
- 21 Nov 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Narayan N, Gowda S, Shivannaiah C. A Randomized Controlled Clinical Trial Comparing the Use of High Purity Type-I Collagen-Based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers. Cureus. 2024 Dec 5;16(12):e75182. doi: 10.7759/cureus.75182. eCollection 2024 Dec.
PubMed 39649230Wolfe EM, Mathis SA, de la Olivo Munoz N, Ovadia SA, Panthaki ZJ. Comparison of human amniotic membrane and collagen nerve wraps around sciatic nerve reverse autografts in a rat model. Biomater Biosyst. 2022 Apr 7;6:100048. doi: 10.1016/j.bbiosy.2022.100048. eCollection 2022 Jun.
PubMed 36824162Mohammed YA, Farouk HK, Gbreel MI, Ali AM, Salah AA, Nourelden AZ, Gawad MMA. Human amniotic membrane products for patients with diabetic foot ulcers. do they help? a systematic review and meta-analysis. J Foot Ankle Res. 2022 Sep 14;15(1):71. doi: 10.1186/s13047-022-00575-y.
PubMed 36104736DiDomenico LA, Orgill DP, Galiano RD, Serena TE, Carter MJ, Kaufman JP, Young NJ, Jacobs AM, Zelen CM. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. Int Wound J. 2018 Dec;15(6):950-957. doi: 10.1111/iwj.12954. Epub 2018 Jul 17.
PubMed 30019528Huang Y, Kyriakides TR. The role of extracellular matrix in the pathophysiology of diabetic wounds. Matrix Biol Plus. 2020 Apr 22;6-7:100037. doi: 10.1016/j.mbplus.2020.100037. eCollection 2020 May.
PubMed 33543031Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005 Jan 12;293(2):217-28. doi: 10.1001/jama.293.2.217.
PubMed 15644549Narayan N, Shivannaiah C, Gowda S. Evaluating the Efficacy of High-Purity Type I Collagen-Based Skin Substitute Versus Dehydrated Human Amnion/Chorion Membrane in the Treatment of Venous Leg Ulcers: A Randomized Controlled Clinical Trial. Cureus. 2025 Jul 30;17(7):e89031. doi: 10.7759/cureus.89031. eCollection 2025 Jul.
PubMed 40747200Narayan N, Ramegowda YH, Raghupathi DS, Chethan S, Gowda S. Biological Skin Substitutes in Pressure Ulcers: High-Purity Type I Collagen-Based Versus Amnion/Chorion Membrane. Cureus. 2025 Aug 25;17(8):e90956. doi: 10.7759/cureus.90956. eCollection 2025 Aug.
PubMed 40862036
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicentric Randomized Controlled Clinical Trial Comparing the Use of High Purity Type-I Collagen-Based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers
- ClinicalTrials.gov ID
- NCT07046403
- Acronym / sponsor ID
- AIMS/IEC/206/2025
- Conditions
- Diabetic Foot Ulcer (DFU)
- Keywords
- Diabetic Foot Ulcer, High Purity Type-I Collagen-Based Skin Substitute, Dehydrated Human Amnion/Chorion Membrane, Randomized Controlled Clinical Trial, Multicentric Study
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Adichunchanagiri Institute of Medical Sciences, B G NagaraUniversity, hospital or other
- Collaborators
- Mysore Medical College and Research Institute, Rajarajeswari Dental College & Hospital, JSS Medical College Hospital
- Study start
- 5 Jul 2025 (actual)
- Primary completion
- 9 Sep 2025 (actual)
- Study completion
- 3 Oct 2025 (actual)
- First posted
- 1 Jul 2025 (actual)
- Results
- Posted 21 Nov 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized controlled clinical investigation in patients suffering from diabetic foot ulcers at multiple centers. The study intends to compare patient outcome data using Standard of Care with Type-I Collagen-based Skin Substitute and Standard of Care with Dehydrated Human Amnion/Chorion Membrane.
Detailed description
The purpose of the present study is to compare the safety and efficacy of high-purity type-I collagen-based skin substitutes (HPTC), which are free from contaminants such as lipids, elastin, and other immunogenic particles, versus dehydrated human amnion/chorion membrane (dHACM) in the treatment of DFUs. This multicentric randomized, controlled clinical trial seeks to provide valuable insights into the best treatment strategy for enhancing healing outcomes and reducing the challenges posed by chronic DFUs.
Study will be carried out as a multicentric randomized, controlled open-label study to evaluate the safety and effectiveness of High Purity Type-I Collagen-based Skin Substitute (HPTC) compared to Dehydrated Human Amnion/Chorion Membrane (dHACM) for treating diabetic foot ulcers (DFUs). The trial will include patients with DFUs treated by wound care specialists at Adichunchanagiri Institute of Medical Sciences (AIMS), B. G. Nagara, Rajarajeswari Medical College and Hospital (RRMCH), Bangalore, JSS Medical College and Hospital (JSS), Mysore and Mysore Medical College and Research Institute (MMC\&RI), Mysore, under the supervision of primary investigator Dr Naveen N. the other principal investigators include Dr Kamal Kumar M, Dr Ravi Shivaiah and Dr Vijay Kumar, respectively. Informed consent will be obtained from all participants prior to any study-related procedures at each of the 3 centres. Each patient will sign an Institutional Ethics Committee / Investigational Review Board (IEC/IRB)-approved consent form, at respective participating centres. IEC/IRB of Adichunchanagiri Institute of Medical Sciences, B. G. Nagara, will be the Designated Ethics Committee (DEC).
The study population will consist of patients seeking treatment for DFUs. Eligible patients will be those willing to participate and comply with scheduled visits on days 7, 10, 14, 17, 21, and 28. The study will include two phases: screening and treatment.
The screening phase aimed to determine patient eligibility for the treatment phase.
Centralized computer-generated block randomization, stratified by centre in a 1:1 ratio will be done. Due to the nature of the interventions, blinding of participants and clinicians is not feasible. However, outcome assessors and data analysts will be blinded to treatment allocation to minimize bias.
The treatment phase of the study will commence with a series of evaluations to ensure patients remained eligible. Participants who will continue to meet the inclusion criteria after the screening phase will be randomly assigned to one of two groups:
- Standard of Care (SOC) with High Purity Type-I Collagen-based Skin Substitute (HPTC).
- Standard of Care (SOC) with Dehydrated Human Amnion/Chorion Membrane (dHACM). Neither the patients nor the clinicians will be blinded to group assignments. The randomization will follow a balanced schedule, using permuted blocks of 12. When a patient will be ready for randomization, the study site will contact a representative from the sponsor, who will open a sequentially numbered opaque envelope to disclose the group assignment, maintaining allocation concealment.
Throughout the 4-week treatment phase, patients will be reassessed on days 7, 10, 14, 17, 21, and 28. The SOC dressing applied in both groups consisted of a three-layer system:
- First layer: Non-adherent, porous paraffin gauze.
- Second layer: Absorbent gauze pads.
- Third layer: Soft roll and Crepe bandage. If the study ulcer was found to be 100% re-epithelialized during the visit, no further study procedures will be conducted at that time. The patient will then be scheduled for a follow-up visit after one week to confirm the healing.
If full healing was not achieved, an evaluation will be carried out to check for any signs of clinical infection. If an infection is confirmed, treatment with topical antimicrobials or oral antibiotics will be permitted, though the use of topical antibiotics will be prohibited.
After this infection assessment, the ulcer would be cleaned, photographed, and debrided at the investigator's discretion to ensure a clean and granulating wound base with minimal adherent slough. The Standard of Care (SOC) will be then re-applied, and patients will be instructed to keep the bandage dry. Additionally, they will be advised to contact or return to the study site if the bandage became soiled or removed.
Study Completion Patients will complete the study 4 weeks after their initial treatment visit. However, if a patient's study ulcer healed before the 4-week period, they will be considered to have completed the study at the time of full healing.
Complete healing will be defined as 100% re-epithelialization of the ulcer with no drainage. Throughout the study, patients will retain the right to decline participation or withdraw at any time without prejudice.
In the event of a patient's withdrawal, their last recorded wound measurement will be carried forward to determine the change in wound size and calculate their final outcome.
Study Outcomes
Primary Endpoint:
- The primary outcome of the study will be the proportion of subjects who achieved improvement in wound healing, as observed on days 7, 10, 14, 17, 21, and 28. The wound closure of the target ulcer will be continuously monitored until the end of the 4-week period.
Secondary Endpoints:
- Vascular Incursion: To assess the infiltration of vascularity in the ulcer bed on day 5 post-treatment initiation (using HPE analysis by taking 2 mm diameter punch biopsy samples).
- Time to Achieve Complete Wound Closure: Time taken for the target ulcer to achieve complete wound closure will be assessed on days 7, 10, 14, 17, 21, and 28.
- Percentage Wound Area Reduction: This will be measured weekly on days 7, 10, 14, 17, 21, and 28 using digital photography.
- Mean Number of Repeated Applications of HPTC: The average number of times the reapplication of High Purity Type-I Collagen-based Skin Substitute (HPTC) to achieve wound closure will be documented as part of the study process.
- To monitor incidence of infection or complications
- To assess patient-reported quality of life
- To evaluate scar quality using validated scales (e.g., Vancouver Scar Scale)
Exploratory Endpoint:
- The appearance, structural stability, and fragility of the newly formed skin will be documented at each visit. Any recurrence of the wound will also be monitored.
Statistical Analysis
Data will be analysed on an intention-to-treat basis. Continuous variables will be summarized using means and standard deviations or medians and interquartile ranges, as appropriate. Categorical variables will be presented as frequencies and percentages. Comparative analyses will include:
- Descriptive statistics for baseline characteristics
- Chi-square tests for categorical outcomes.
- Independent t-tests or Mann-Whitney U tests for continuous outcomes.
- Kaplan-Meier survival analysis for time-to-event data, with log-rank tests to compare groups.
Multivariable regression models will adjust for potential confounders, such as baseline wound size and patient comorbidities.
Sample Size Calculation Based on previous studies, assuming a 20% difference in the primary outcome between groups, with 60% healing in the dHACM group and 80% in the HPTC group, a sample size of 60 participants per group (total N=60) combined from the 4 centres will provide 80% power to detect this difference at a 5% significance level, accounting for a 10% dropout rate.
Ethical Considerations The study will adhere to the Declaration of Helsinki principles and Good Clinical Practice guidelines. Ethical approval will be obtained from Institutional Ethics Committee of all participating centres. Informed consent will be obtained from all participants before enrolment. Adverse events will be monitored and reported. Participant confidentiality will be maintained, and data will be anonymized. Findings will be submitted to peer-reviewed journals and presented at relevant conferences.
Timeline Recruitment: 1 month Intervention \& follow-up assessment: 3 months Data analysis and reporting: 1 month
Potential Implications This study aims to provide robust evidence on the comparative efficacy of HPTC and dHACM in managing DFUs. If HPTC proves superior to dHACM alone, it could establish a standard in treating DFUs, reducing healing time. Positive findings could influence clinical practice guidelines, offering alternative treatment options that may enhance patient outcomes and reduce healthcare costs.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High Purity Type-I Collagen-based Skin Substitute and SOC | Active comparator | Device: High Purity Type-I Collagen-based Skin Substitute and SOCThe SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) |
| Human Amnion/Chorion Membrane and SOC | Active comparator | Device: Dehydrated Human Amnion / Chorion Membrane and SOCThe SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Subjects must be at least 18 years of age or older.
- Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
- At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 10.0 cm2 measured post debridement using a ruler to measure wound area.
- The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
- The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
Key exclusion criteria (15 listed)
- A subject known to have a life expectancy of <6 months.
- If the target ulcer is infected or if there is cellulitis in the surrounding skin.
- Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
- A subject that has an infection in the target ulcer that requires systemic antibiotic therapy.
- A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Purity Type-I Collagen-based Skin Substitute and SOCThe SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) | Device | High Purity Type-I Collagen-based Skin Substitute and SOC |
| Dehydrated Human Amnion / Chorion Membrane and SOCThe SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage) | Device | Human Amnion/Chorion Membrane and SOC |
Primary outcome
Percentage Change in Wound Area
Time frame: 5 weeks
The primary outcome of the study will be the percentage change in wound area, assessed at 1, 2,3, and 4 weeks, and week 5 reported measured manually with digital photography.
9 secondary outcomes
Histopathological Analysis
Time frame: 5 days
Histopathological Analysis - Capillary Density (Vessels Per mm²)
Time frame: 5 days
Percentage of Participants to Obtain Complete Wound Closure
Time frame: 5 weeks
Time to Achieve Complete Wound Closure
Time frame: 5 weeks
Percentage of Participants Achieving ≥50% Wound Healing
Time frame: 5 weeks
Mean Number of Applications of HPTC / dHACM
Time frame: 4 weeks
Number of Participants With Adverse Events
Time frame: 4 weeks
Patient-Reported Quality of Life Assessed Using Diabetic Foot Ulcer Scale - Short Form (DFS-SF)
Time frame: 5 weeks
Healed Wound Appearance Assessment Using Vancouver Scar Scale
Time frame: 5 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 39649230Narayan N, Gowda S, Shivannaiah C. A Randomized Controlled Clinical Trial Comparing the Use of High Purity Type-I Collagen-Based Skin Substitute vs. Dehydrated Human Amnion/Chorion Membrane in the Treatment of Diabetic Foot Ulcers. Cureus. 2024 Dec 5;16(12):e75182. doi: 10.7759/cureus.75182. eCollection 2024 Dec.
- Background: PubMed 36824162Wolfe EM, Mathis SA, de la Olivo Munoz N, Ovadia SA, Panthaki ZJ. Comparison of human amniotic membrane and collagen nerve wraps around sciatic nerve reverse autografts in a rat model. Biomater Biosyst. 2022 Apr 7;6:100048. doi: 10.1016/j.bbiosy.2022.100048. eCollection 2022 Jun.
- Background: PubMed 36104736Mohammed YA, Farouk HK, Gbreel MI, Ali AM, Salah AA, Nourelden AZ, Gawad MMA. Human amniotic membrane products for patients with diabetic foot ulcers. do they help? a systematic review and meta-analysis. J Foot Ankle Res. 2022 Sep 14;15(1):71. doi: 10.1186/s13047-022-00575-y.
- Background: PubMed 30019528DiDomenico LA, Orgill DP, Galiano RD, Serena TE, Carter MJ, Kaufman JP, Young NJ, Jacobs AM, Zelen CM. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. Int Wound J. 2018 Dec;15(6):950-957. doi: 10.1111/iwj.12954. Epub 2018 Jul 17.
- Background: PubMed 33543031Huang Y, Kyriakides TR. The role of extracellular matrix in the pathophysiology of diabetic wounds. Matrix Biol Plus. 2020 Apr 22;6-7:100037. doi: 10.1016/j.mbplus.2020.100037. eCollection 2020 May.
- Background: PubMed 15644549Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005 Jan 12;293(2):217-28. doi: 10.1001/jama.293.2.217.
- Background: PubMed 40747200Narayan N, Shivannaiah C, Gowda S. Evaluating the Efficacy of High-Purity Type I Collagen-Based Skin Substitute Versus Dehydrated Human Amnion/Chorion Membrane in the Treatment of Venous Leg Ulcers: A Randomized Controlled Clinical Trial. Cureus. 2025 Jul 30;17(7):e89031. doi: 10.7759/cureus.89031. eCollection 2025 Jul.
- Background: PubMed 40862036Narayan N, Ramegowda YH, Raghupathi DS, Chethan S, Gowda S. Biological Skin Substitutes in Pressure Ulcers: High-Purity Type I Collagen-Based Versus Amnion/Chorion Membrane. Cureus. 2025 Aug 25;17(8):e90956. doi: 10.7759/cureus.90956. eCollection 2025 Aug.
- Individual participant dataSharing planned: No
Related trials for Diabetic Foot Ulcer (DFU)
Recruiting
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
Diabetic Foot Ulcer (DFU), Diabetic Symmetrical Polyneuropathy
Active, not recruiting
Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers
Diabetic Foot Ulcer (DFU)
Recruiting
Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
Diabetic Foot Ulcer, Foot Ulcer Chronic
Not yet recruiting
DiaFootCare to Promote Self-Care of Diabetic Foot Ulcers in Oman
Diabetic Foot Ulcer (DFU), Diabetes Mellitus
Not yet recruitingPhase 1/2
Evaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Diabetic Foot Ulcers
Diabetic Foot Ulcer (DFU), Ulcer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Prema Dhanraj, MS, MCh study chair
Rajarajeshwari Medical College and Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High Purity Type-I Collagen-based Skin Substitute and SOC and Dehydrated Human Amnion / Chorion Membrane and SOC in people with Diabetic Foot Ulcer (DFU), run by Adichunchanagiri Institute of Medical Sciences, B G Nagara at 4 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage Change in Wound Area (time frame: 5 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07046403, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.